Citadel Advisors’s Design Therapeutics DSGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.83M | Sell |
840,793
-122,667
| -13% | -$413K | ﹤0.01% | 2387 |
|
|
2025
Q1 | $3.72M | Buy |
963,460
+4,667
| +0.5% | +$18K | ﹤0.01% | 2017 |
|
|
2024
Q4 | $5.92M | Buy |
958,793
+383,243
| +67% | +$2.36M | ﹤0.01% | 1671 |
|
|
2024
Q3 | $3.1M | Buy |
575,550
+270,920
| +89% | +$1.46M | ﹤0.01% | 2133 |
|
|
2024
Q2 | $1.02M | Sell |
304,630
-570,147
| -65% | -$1.91M | ﹤0.01% | 3014 |
|
|
2024
Q1 | $3.53M | Sell |
874,777
-957,477
| -52% | -$3.86M | ﹤0.01% | 2036 |
|
|
2023
Q4 | $4.86M | Sell |
1,832,254
-868,299
| -32% | -$2.3M | ﹤0.01% | 1671 |
|
|
2023
Q3 | $6.37M | Sell |
2,700,553
-155,553
| -5% | -$367K | ﹤0.01% | 1448 |
|
|
2023
Q2 | $18M | Sell |
2,856,106
-9,061
| -0.3% | -$57.1K | ﹤0.01% | 869 |
|
|
2023
Q1 | $16.5M | Buy |
2,865,167
+362,606
| +14% | +$2.09M | ﹤0.01% | 964 |
|
|
2022
Q4 | $25.7M | Buy |
2,502,561
+80,829
| +3% | +$829K | 0.01% | 746 |
|
|
2022
Q3 | $40.5M | Sell |
2,421,732
-123,926
| -5% | -$2.07M | 0.01% | 490 |
|
|
2022
Q2 | $35.6M | Buy |
2,545,658
+10,956
| +0.4% | +$153K | 0.01% | 528 |
|
|
2022
Q1 | $40.9M | Hold |
2,534,702
| – | – | 0.01% | 519 |
|
|
2021
Q4 | $54.3M | Sell |
2,534,702
-37,828
| -1% | -$810K | 0.01% | 450 |
|
|
2021
Q3 | $37.8M | Buy |
2,572,530
+6,382
| +0.2% | +$93.8K | 0.01% | 566 |
|
|
2021
Q2 | $49.9M | Buy |
2,566,148
+31,445
| +1% | +$612K | 0.01% | 493 |
|
|
2021
Q1 | $75.8M | Buy |
+2,534,703
| New | +$75.8M | 0.02% | 303 |
|